Ignite Creation Date:
2024-05-06 @ 5:44 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05418309
Status:
UNKNOWN
Last Update Posted:
2022-06-14
First Post:
2022-06-09
Brief Title:
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable a Multi-center Study
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Tianjin Medical University Second Hospital
Organization Data
Organization:
Tianjin Medical University Second Hospital
Class:
OTHER
Study ID:
TRUCE-22
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tianjin Medical University Second Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None